There are increasing calls to conduct randomized controlled trials to effectively test the hypothesis that AT1R blockade may be a novel therapeutic approach for the treatment of Alzheimer’s disease [22, 117–119], and in particular including patients at the very early stages of the disease [120]. The gene discussed is AGTR1; the disease is early-onset autosomal dominant Alzheimer disease.